In this issue of Cancer Cell, Sharma et al. report that ipilimumab and nivolumab combination achieved impressive response rates in patients with metastatic castration-resistant prostate cancer (mCRPC). But this regimen produced high rates of toxicity, treatment-related discontinuation, and death. Tolerability needs improvement for this combination to benefit more men with mCRPC.

中文翻译：

---

转移性去势抵抗性前列腺癌的双重检查点封锁：只是一个良心还是真正的CheckMate？

在本期《癌细胞》中，Sharma等人。报告指出，ipilimumab和nivolumab联合使用可治疗转移性去势抵抗性前列腺癌（mCRPC）患者。但是这种方案产生高毒性，与治疗相关的停药和死亡。这种组合的耐受性需要提高，以使更多的mCRPC男性受益。